Macrophage-derived CCL20 promotes abdominal aortic aneurysm progression via lymphocytes CCR6.

阅读:2
作者:Ren Qingnan, Sun Tianyong, Shen Song, Cao Yuanbin, Wei Li, Zhao Yang, Wan Fengxin, Sui Ping, Xiao Ke, Bai Hao, Guo Dachuan, He Qi, Zhi Mengfan, Yang Jianmin, Jiang Jianjun, Zhang Wencheng, Ding Xiangjiu
INTRODUCTION: Abdominal aortic aneurysm (AAA) is a chronic vascular disease marked by chronic inflammation and immune dysregulation. The C-C motif chemokine ligand 20 (CCL20) - C-C motif chemokine receptor type 6 (CCR6) axis modulates immune responses in vascular diseases, but its role in AAA remains unclear. This study investigates the involvement of the CCL20-CCR6 axis in AAA formation. METHODS: Single-cell RNA sequencing datasets and bulk RNA sequencing datasets were analyzed to assess cellular composition and transcriptional changes. Transcriptomic analysis, enzyme-linked immunosorbent assay, UK Biobank database analysis, CellChat analysis, immunofluorescence staining, and mouse models were employed to explore the CCL20-CCR6 axis in AAA. RESULTS: Substantial immune cell infiltration (T lymphocytes & B lymphocytes) and loss of structural cells (fibroblasts, endothelial cells and smooth muscle cells) were identified using single-cell RNA sequencing datasets. Macrophage polarization was imbalanced, with enriched M1-like macrophages and elevated CCL20 secretion. Macrophages could promote the formation of AAA by recruiting a large number of immune cells via the CCL20-CCR6 axis. In vitro, CCL20 neutralization reduced immune cell recruitment; in vivo, the knockdown of this axis inhibited AAA progression. CONCLUSIONS: Macrophage-derived CCL20 aggravates lymphocyte recruitment via the CCR6, promoting AAA progression. CCL20 may serve as a biomarker for AAA. Targeting the CCL20-CCR6 axis could inhibit immune recruitment and AAA progression.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。